Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol

Neuropsychopharmacology

Volumn 22, Issue 3, 2000, Pages 311-319

  Liu, Shi K ^a   Chen, Wei J ^b   Chang, Ching Jui ^a,c   Lin, Hsin Nan ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Continuous Performance Test (CPT); Double blind; Extrapyramidal side effects; Haloperidol; Risperidone; Vulnerability indicator

Indexed keywords

HALOPERIDOL; RISPERIDONE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; PERFORMANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033960819     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00137-2     Document Type: Article

References (53)

1. Addington J., Addington D. Neurocognitive functioning in schizophrenia. A trial of risperidone versus haloperidol Can J Psychiatry. 42:1997;983.
2. Diagnostic and Statistical Manual of Mental Disorders. Third Edition, Revised:1987;APA, Washington, DC.
3. Asarnow R.F., MacCrimmon D.J. Residual performance deficit in clinically remitted schizophrenics. A marker of schizophrenia? J Abnorm Psychol. 87:1978;597-608.
4. Brockel B.J., Fowler S.C. Effects of chronic haloperidol on reaction time and errors in a sustained attention task. Partial reversal by anticholinergics and by amphetamine J Pharmacol Exp Ther. 275:1995;1090-1098.
5. Bushnell P.J., Oshiro W.M., Padnos B.K. Detection of visual signals by rats. Effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention Psychopharmacol. 134:1997;230-241.
6. Bymaster F.P., Heath I., Hendrix J.C., Shannon H.E. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther. 267:1993;16-24.
7. Carman J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia. A meta-analysis Int Clin Psychopharmacol. 10:1995;207-213.
8. Chen W.J., Hsiao C.K., Hsiao L.-L., Hwu H.-G. Performance of the Continuous Performance Test among community samples. Schizophr Bull. 24:1998;163-174. a.
9. Chen W.J., Liu S.K., Chang C.-J., Lien Y.-J., Chang Y.-H., Hwu H.-G. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry. 155:1998;1214-1220. b.
10. Cheng J.J., Ho H., Chang C.J., Lan S.Y., Hwu H.G. Positive and Negative Syndrome Scale (PANSS). Establishment and reliability study of a Mandarin Chinese language version Chinese Psychiatry. 10:1996;251-258.
11. Chouinard G., Ross-Chouinard A., Annable L., Jones B.D. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci. 7:1980;233.
12. Cornblatt B.A., Lenzenweger M.F., Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version. II. Contrasting attentional profiles in schizophrenic and depressed patients Psychiatry Res. 29:1989;65-85.
13. Cornblatt B.A., Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull. 20:1994;31-46.
14. Cornblatt B.A., Obuchowski M., Schnur D.B., O'Brien J.D. Attention and clinical symptoms in schizophrenia. Psychiatr Quart. 20:1997;31-46.
15. Earle-Boyer E.A., Serper M.R., Davidson M., Harvey P.D. Continuous performance tests in schizophrenic patients. Stimulus and medication effects on performance Psychiatry Res. 37:1991;47-56.
16. Epstein J.I., Keefe R.S.E., Roitman S.L., Harvey P.D., Mohs R.C. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biol Psychiatry. 39:1996;902-905.
17. Erickson W.D., Yellin A.M., Hopwood J.H., Realmuto G.M., Greenberg L.M. The effects of neuroleptics on attention in adolescent schizophrenics. Biol Psychiatry. 19:1984;745-753.
18. Finkelstein J.R.J., Cannon T.D., Gur R.E., Gur R.C., Moberg P. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol. 106:1997;203-212.
19. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schulz S.C., Weinberg D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 162:1993;43-48.
20. Harvey P.D., Keefe R.S., Moskowitz J., Putnam K.M., Mohs R.C., Davis K.L. Attentional markers of vulnerability to schizophrenia. Performance of medicated and unmedicated patients and normals Psychiatry Res. 33:1990;179-188.
21. Harvey P.D., Keefe R.S.E., Mitroupolou V., Dupre R., Roitman S.L., Mohs R.C., Siever L.J. Information-processing markers of vulnerability to schizophrenia. Performance of patients with schizotypal and nonschizotypal personality disorders Psychiatry Res. 60:1996;49-56.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
23. Kay S.R. Positive and Negative Syndromes in Schizophrenia. Assessment and Research:1991;Brunner/Mazel, New York.
24. Lenzenweger M.F., Cornblatt B.A., Putnick M. Schizotypy and sustained attention. J Abnorm Psychol. 100:1991;84-89.
25. Leysen J.E., Janssen P.M.F., Megens A.A.H.P., Schotte A. Risperidone. A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity J Clin Psychiatry. 55:1994;5-12.
26. Liu S.K., Chang C.-J., Lin H.-N. A double-blind study of risperidone versus haloperidol treatment in acute schizophrenic patients. Chinese Psychiatry. 10:1996;365-376. (in Chinese).
27. Liu S.K., Hwu H.-G., Chen W.J. Clinical symptom dimensions and deficits on the Continuous Performance Test in schizophrenia. Schizophr Res. 25:1997;211-219.
28. McGaughy J., Sarter M. Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation. Effects of Physostigmine and FG 7142 Behav Neurosci. 112:1998;1519-1525.
29. Mirsky A.F., Delisi L.E., Buchsbaum M.S., Quinn O.W., Schwerdt P., Siever L.J., Mann L., Weingartner H., Zec R., Sostek A., Alterman I., Revere V., Dawson S.D., Zahn T.P. The Genain Quadruplets. Psychological studies Psychiatry Res. 13:1984;77-93.
30. Mirsky A.F., Yardley S.L., Jones B.P., Walsh D., Kendler K.S. Analysis of the attention deficit in schizophrenia. A study of patients and their relatives in Ireland J Psychiatr Res. 29:1995;23-42.
31. Mussgay L., Hertwig R. Signal detection indices in schizophrenics on a visual, auditory and bimodal Continuous Performance Test. Schizophr Res. 3:1990;303-310.
32. Nestor P.G., Faux S.F., McCarley R.W., Sands S.F., Horvath T.B., Peterson A. Neuroleptics improve sustained attention in schizophrenia. A study using signal detection theory Neuropsychopharmacol. 4:1991;145-149.
33. Norusis M.J. The Statistical Package for Social Sciences (SPSS), Manual of Reference. 1986;SPSS, Inc, Chicago.
34. Nuechterlein K.H., Dawson M.E. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull. 10:1984;300-312.
35. Nuechterlein K.H. Vigilance in schizophrenia and related disorders. Steinhauer S.R., Gruzelier J.H., Zubin J. Handbook of Schizophrenia, Vol. 5. Neuropsychology, Psychophysiology and Information Processing:1991;397-433 Elsevier, Amsterdam.
36. Nuechterlein K.H., Dawson M.E., Ventura J., Fogelson D., Gitlin M., Mintz J. Testing vulnerability models. Stability of potential vulnerability indicators across clinical state Häfner H., Gattaz W.F. Search for the Causes of Schizophrenia, Vol.II. 1991;177-191 Springer-Verlag, Berlin.
37. Nuechterlein K.H., Dawson M.E., Gitlin M., Ventura J., Goldstein M.J., Snyder K.S., Yee C.M., Mintz J. Developmental processes in schizophrenic disorders. Longitudinal studies of vulnerability and stress Schizophr Bull. 18:1992;387-425.
38. Nurnberger J.I. Jr., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy- Friedman J., Severe J.B., Malaspina D., Reich T., collaborators from the NIMH Genetics Initiative Diagnostic Interview for Genetic Studies. Rationale, unique features, and training Arch Gen Psychiatry. 51:1994;849-859.
39. Orzack M.H., Kornetsky C. Attention dysfunction in chronic schizophrenia. Arch Gen Psychiatry. 14:1966;323-327.
40. Orzack M.H., Kornetsky C., Freeman H. The effect of daily carphenazine on attention in the schizophrenic patient. Psychopharmacologia. 8:1967;31-38.
41. Orzack M.H., Kornetsky C. Environmental and familial predictors of attention behavior in chronic schizophrenics. J Psychiatr Res. 9:1971;21-29.
42. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia. A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol Br J Psychiatry. 166:1995;712-726.
43. Rossi A., Mancini F., Stratta P., Mattei P., Gismondi R., Pozzi F., Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia. An open study Acta Psychiatr Scand. 95:1997;40-43.
44. Rosvold H.E., Mirsky A.F., Sarason I., Bransome E.D. Jr., Beck L.H. A Continuous Performance Test of brain damage. J Consult Psychol. 20:1956;343-350.
45. Rutschmann J., Cornblatt B., Erlenmeyer-Kimling L. Sustained attention in children at risk for schizophrenia. Report on a Continuous Performance Test Arch Gen Psychiatry. 34:1977;571-575.
46. Seidman L.J., Van Manen K.J., Turner W.M., Gamser D.M., Faraone S.V., Goldstein J.M., Tsuang M.T. The effects of increasing resource demand on vigilance performance in adults with schizophrenia or developmental attentional/learning disorders. A preliminary study Schizophr Res. 34:1998;101-112.
47. Serper M.R., Bergman R.L., Harvey P.D. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res. 32:1990;281-288.
48. Spohn H.E., Lacoursiere R.B., Thompson K., Coyne L. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Arch Gen Psychiatry. 34:1977;633-644.
49. Strandburg R.J., Marsh J.T., Brown W.S., Asarnow R.F., Guthrie D., Higa J. Event- related potential correlates of impaired attention in schizophrenic children. Biol Psychiatry. 27:1990;1103-1115.
50. Tracy J.L., Monaco C.A., Abraham G., Josiassen R.C., Pollock B.G. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry. 59:1998;184-188.
51. Van Cauteren H., Megens A.H.P.A., Lampo A., Meuldermans W. Risperidone. An overview of animal pharmacology, toxicology and pharmacokinetics Kane J.M., Moller H.-J., Awouters F. Serotonin in Antipsychotic Treatment. Mechanisms and Clinical Practice:1996;253-276 Marcel Dekker, New York.
52. Walker E., Shaye J. Familial schizophrenia. A predictor of neuromotor and attentional abnormalities in schizophrenia Arch Gen Psychiatry. 39:1982;1153-1156.
53. Wohlberg G.W., Kornetsky C. Sustained attention in remitted schizophrenics. Arch Gen Psychiatry. 28:1973;533-537.